Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lattice Biologics Ltd V.LBL.H

Alternate Symbol(s):  LBLTF

Healthcare Biotechnology
Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.


TSXV:LBL.H - Post by User

Lattice Biologics Ltd
Bullboard Posts
User Avatar Image
(325)
•••
Comment by Actuarialon Mar 06, 2017 3:34pm
158 Views
Post# 25939327

RE:RE:Not bad

RE:RE:Not badLattice swithced to direct sales is a fundamentally change in marketing strategy - KOL seems not working well I guess. AmnioVisc sale seems growing at a rate of at least 37% quarter over quarter. Worst scenario, by the end of 2019, AmnioVisc alone would be sufficient to produce $1M revenue per month. Given Lattice plan to increase their direct sale reps from 4 to 15-20, I expect it would reach the monthly $1M revenue milestone sooner. Keep in mind that Anika Threa has only one core pipeline while Lattice has more - its potential is huge. Lattice just need to strengthen its sale team, which Lattice already started to take actions.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities